Τόμος 33 (2015) – Τεύχος 1 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 33 (2015) – Issue 1 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Η Εκτίμηση του Κόστους και της Αποτελεσματικότητας των Φαρμάκων της Ψωρίασης στην Ελλάδα

Γ. Κόκλα, Π. Γαλάνης, Δ. Καϊτελίδου, Ά. Μεχίλι, Ε. Πλέσσα, Μ. Διομήδους

Τομέας Δημόσιας Υγείας, Τμήμα Νοσηλευτικής, Εθνικό και Καποδιστριακό Πανεπιστήμιο, Αθήνα, Ελλάς

G. Kokla, P. Galanis, D. Kaitelidou, A. Mehili, H. Plessa, M. Diomidous

Department of Public Health, Faculty of Nursing, University of Athens, Papadiamantopoulou 123,
GR 11527, Athens, Hellas

2. Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P.: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64(suppl 2): ii14–17 (2005)

3. Laws P.M., Young D.H.S.: Current and emerging systemic treatment strategies for psoriasis. Drugs 172(14): 1867-1880 (2012)

4. Karczewski J., Poniedziałek B., Rzymski P., Adamski Z.: Factors affecting response to biologic treatment in psoriasis. Dermatol Ther. 27(6): 323-330 (2014)

5. Parisi R., Symmons D.P.M., Griffiths C.E.M., Ashcroft D.M.: Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133(2): 377-385 (2013)

6. Gelfand J.M., Stern R.S., Nijsten T., Feldman S.R., Thomas J., Kist J., Rolstad T, Margolis DJ.: The prevalence of psoriasis in African Americans: results from a populationbased study. J. Am. Acad. Dermatol. 52(1): 23-26 (2005)

7. Naldi L.: Epidemiology of Psoriasis. Curr. Drug Targets Inflamm. Allergy 3(2): 121-128 (2004)

8. THOMAS P. HABIF. Δερματικά Νοσήματα: Διάγνωση και Θεραπεία (2η έκδοση). ΠΑΡΙΣΙΑΝΟΥ Α.Ε. ΑΘΗΝΑ; 2007. 752 p.

9. iefimerida.gr. Νέο επαναστατικό φάρμακο κατά της ψωρίασης: Αντιμετωπίζει τη νόσο έως και στο 100% -Πότε θα κυκλοφορήσει [Internet]. iefimerida.gr. 2014 [cited 2014 Nov 13]. Available from: http://www.iefimerida.gr/news/17474 /%CE%BD%CE%AD%CE%BF-%CE%B5%CF%80%CE%B1%CE%BD%CE%B %CF%83%CF%84%CE%B1%CF%84%CE%B9%CE%BA%CF%8C-%CF%86%CE%AC%CF%81%CE%BC%CE%B1%CE%BA%CE%BF-%CE%BA%CE%B1%CF%8 %CE%AC-%CF%84%CE%B7%CF%82-%CF%88%CF%89%CF%81%CE%AF%CE%B1%CF%83%CE%B7%CF%82-%E2%80%93-%CE%B1%CE%BD%CF%84%CE%B9%CE%BC%CE%B5%CF%84%CF%89%CF%80%CE%AF%CE%B6%CE%B5%CE%B9-%CF%84%CE%B7-%CE%BD%CF%8C%CF%83%CE%BF-
%CE%AD%CF%89%CF%82-%CE%BA%CE%B1%CE%B9-%CF%83%CF%84%CE%BF-90-%CF%80%CF%8C%CF%84%CE%B5-%CE%B8

10. Δημήτριος Ιωαννίδης. Ψωρίαση [Internet]. 2008 [cited 2014 Nov 13]. Available from: http://helioseie.ekt.gr/EIE/bitstream/10442/403/1/M01.050.12.pdf

11. Leman J.A., Burden A.D.: Recognition and treatment of psoriasis in children. Curr. Paediatr. 13(6): 418-422 (2003)

12. Liu J.-.T, Yeh H.-M., Liu S.-Y., Chen K.-T.: Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J. Orthop. 5(4): 537-543 (2014)

13. Parish L.C., Brenner S., Ramos-e-Silva M., Parish J.L. (Eds): Manual of Gender Dermatology. P. 320, Jones & Bartlett Publishers; 2010

14. Swanbeck G., Inerot A., Martinsson T., Enerbäck C., Enlund F., Samuelsson L., Yhr M, Wahlström J.: Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br. J. Dermatol. 137(6): 939-942 (1997)

15. Vincent N., Ramya D.D., Vedha H.B.: Progress in Psoriasis Therapy via Novel Drug Delivery Systems. Dermatol Rep. 6(1): 5451 (2014)

16. Li Y., Wang D., Wang Y., Shi G.: Progress of biological agents on psoriatic arthritis. Curr. Pharm. Biotechnol. 15(6): 525-534 (2014)

17. Schreiber S., Luger T., Mittendorf T., Mrowietz U., Müller-Ladner U., Schröder J., Stallmach A., Bokemeyer B.: Evolution of biologicals in inflammation medicine – Biosimilars in gastroenterology, rheumatology and dermatology. Deutsche medizinische Wochenschrift (1946) 139(47): 2399-2404 (2014)

18. Fowler J.F., Duh M.S., Rovba L., Buteau S., Pinheiro L., Lobo F., Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.: The impact of psoriasis on health care costs and patient work loss. J. Am. Acad. Dermatol. 59(5): 772-780 (2008)

19. Wu N., Lee Y.-C.D., Shah N., Harrison D.J.: Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clin. Ther. 36(8): 1231-1241 (2014) 1241.e1–3.

20. Costs of psoriasis treatments outpace inflation [Internet]. ScienceDaily. [cited 2014 Nov 15]. Available from: http://www.sciencedaily.com/releases/2010/01/100118161939.htm

21. Ghatnekar O., Ljungberg A., Wirestrand L.-E., Svensson A.: Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a crosssectional study. Eur. J. Dermatol. 22(2): 238-245 (2012)

22. Antonio Dominguez Gil-Hurle, Diego Moreno Ramirez, Diego Garcia Molinaro, Christian Cmpo Sien. Annual cost of biologic therapies for the treatment of moderte to severe plaque psoriasis in Spain [Internet]. [cited 2014 Nov 15]. Available from:
http://www.ispor.org/research_pdfs/39/pdffiles/PSS20.pdf

23. Σαμούτης Αλέξης: Μελέτη Ποιότητας Ζωής ασθενών με μέτρια και σοβαρή ψωρίαση και οι οικονομικές συνέπειες της ασθένειας στην Ελλάδα. [Internet]. [cited 2014 Oct 10]. Available from: http://www.didaktorika.gr/eadd/simplesearch?
query=%CE%A3%CE%B1%CE%BC%CE%BF%C F%8D%CF%84%CE%B7%CF%82&submit.x=6&submit.y=6

24. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., Zhou B., Dooley L.T., Kavanaugh A.; IMPACT 2 Trial Investigators: Infliximab improves signs
and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64(8): 1150-1157 (2005)

25. Genovese M.C., Mease P.J., Thomson G.T.D., Kivitz A.J., Perdok R.J., Weinberg M.A., Medich J., Sasso E.H.; M02-570 Study Group: Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J. Rheumatol. 34(5): 1040-1050 (2007) Erratum in: J. Rheumatol. 34(6): 1439 (2007)

26. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., Salonen D., Rubenstein J., Sharp J.T., Tsuji W.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50(7): 2264-2272 (2004)

27. Demirsoy E.O., Kıran R., Salman S., Cağlayan C., Aktürk A.S., Bayramgurler D., Bilen N.: Effectiveness of systemic treatment agents on psoriatic nails: a comparative
study. J. Drugs Dermatol. 12(9): 1039-1043 (2013)

28. Cawson M.R., Mitchell S.A., Knight C., Wildey H., Spurden D., Bird A., Orme M.E.: Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet. Disord. 15: 26 (2014)

29. Ruano J., Isla-Tejera B., Jiménez-Puya R., Rodriguez-Martin A., Cárdenas M., Gómez F., Vélez A.A., Del Prado-Llergo J.R., Moreno-Giménez J.C.: Long-Term Cost-
Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis. Dermatol. Ther. (Heidelb) 3(2): 131-142 (2013)

30. Ahn C.S., Gustafson C.J., Sandoval L.F., Davis S.A., Feldman S.R.: Cost effectiveness of biologic therapies for plaque psoriasis. Am. J. Clin. Dermatol. 14(4): 315-326 (2013)

31. Gladman D.D., Bombardier C., Thorne C., Haraoui B., Khraishi M., Rahman P., Bensen W., Syrotuik J., Poulin-Costello M.: Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J. Rheumatol. 38(7): 1355-1362 (2011)

32. Schmitt-Rau K., Rosenbach T., Radtke M.A., Augustin M.: Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatol. Basel Switz. 221(3): 236-242 (2010)

33. De Portu S., Del Giglio M., Altomare G., Arcangeli F., Berardesca E., Calzavara-Pinton P., Lotti T., Martini P., Peserico A., Simonacci M., Vena G.A., Girolomoni G.:
Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatol Ther. 23 Suppl 1: S7-13 (2010) Erratum in: Dermatol. Ther. 23(4): 434 (2010). Pinton, Piergiacomo Calzavara [corrected to Calzavara-Pinton, Piergiacomo].

34. Cummins E., Asseburg C., Punekar Y.S., Shore E., Morris J., Briggs A., Fenwick E.: Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res. 14(1): 15-23 (2011)

35. Atteno M., Peluso R., Costa L., Padula S., Iervolino S., Caso F., Sanduzzi A., Lubrano E., Del Puente A., Scarpa R.: Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin. Rheumatol. 29(4): 399-403 (2010)

36. Navarini A.A., Laffitte E., Conrad C., Piffaretti P., Brock E., Ruckdaeschel S., Trüeb R.M.: Estimation of cost-ofillness in patients with psoriasis in Switzerland. Swiss Med Wkly 140(5-6): 85-91 (2010)

37. Jiamton S., Suthipinittharm P., Kulthanan K., Chularojanamontri L., Wongpraparut C., Silpa-archa N., Sirikudta W.: Clinical characteristics of Thai patients with psoriasis. J. Med. Assoc. Thail Chotmaihet Thangphaet. 95(6): 795-801
(2012)

38. Alamanos Y., Papadopoulos N.G., Voulgari P.V., Siozos C., Psychos D.N., Tympanidou M., Drosos A.A.: Epidemiology of psoriatic arthritis in northwest Greece, 1982-2001. J. Rheumatol. 30(12): 2641-2644 (2003)

39. Liu Y., Wu E.Q., Bensimon A.G., Fan C.-P.S., Bao Y., Ganguli A., Yang M., Cifaldi M., Mulani P.: Cost per responder associated with biologic therapies for Crohn’s
disease, psoriasis, and rheumatoid arthritis. Adv. Ther.29(7): 620-634 (2012)

40. Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, Sculpher M.: Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford) 50(suppl 4): iv39-47 (2011)

41. Wang S.-H., Chi C.-C., Hu S.: Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. Int. J. Dermatol. 53(9): 1151-1156 (2014)

42. Chi C.-C., Wang S.-H.: Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a metaanalysis and cost-efficacy analysis using the intention-totreat principle. BioMed. Res. Int. 2014: 862851 (2014)

43. Puig L.: Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs switch to another biologic after
failure of maintenance therapy. Actas Dermo-Sifiliográficas 105(4): 401-412 (2014)

44. Ferrándiz C., García A., Blasco A.J., Lázaro P.: Costefficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 26(6): 768-777 (2012)

45. Anis A.H., Bansback N., Sizto S., Gupta S.R., Willian M.K., Feldman S.R.: Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J. Dermatol. Treat. 22(2): 65-74 (20110)

46. Blasco A.J., Lázaro P., Ferrándiz C., García-Díez A., Liso J.: [Efficiency of biologic agents in the treatment of moderate to severe psoriasis]. Actas Dermo-Sifiliográficas
100(9): 792–803 (2009)

47. Nelson A.A., Pearce D.J., Fleischer A.B., Balkrishnan R., Feldman S.R.: Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J. Am. Acad. Dermatol. 58(1): 125-135 (2008)

48. Terranova L., Mattozzi C., Richetta A.G., Mantuano M., Cardosi L., Teruzzi C.: Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system. G. Ital. Dermatol.
Venereol. 149(1): 131-143 (2014)

49. Rodgers M., Epstein D., Bojke L., Yang H., Craig D., Fonseca T., Myers L., Bruce I., Chalmers R., Bujkiewicz S., Lai M., Cooper N., Abrams K., Spiegelhalter D., Sutton A., Sculpher M., Woolacott N.: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol, Assess Winch. Engl. 15(10): i-xxi, 1-329 (2011)

50. Bravo Vergel Y., Hawkins N.S., Claxton K., Asseburg C., Palmer S., Woolacott N., Bruce I.N., Sculpher M.J.: The cost-effectiveness of etanercept and infliximab for the
treatment of patients with psoriatic arthritis. Rheumatol. Oxf. Engl. 46(11): 1729-1735 (2007)

51. Driessen R.J.B., Bisschops L.A., Adang E.M.M., Evers A.W., Van De Kerkhof P.C.M., De Jong E.M.G.J.: The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br. J. Dermatol. 162(6): 1324-1329 (2010)